Dicerna nabs Rare Pediatric Disease tag for nedosiran for primary hyperoxaluria

The FDA has granted rare pediatric disease designation to Dicerna Pharmaceuticals’ (NASDAQ:DRNA) nedosiran, an investigational RNAi therapy being developed as a once-monthly treatment for primary hyperoxaluria, a family of ultra-rare, life-threatening genetic disorders that cause complications in the kidneys.

Rare Pediatric Disease Designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party.

https://seekingalpha.com/news/3584095-dicerna-nabs-rare-pediatric-disease-tag-for-nedosiran-for-primary-hyperoxaluria